New drug anktiva tested for long COVID relief

NCT ID NCT07123727

Recruiting now Disease control Sponsor: ImmunityBio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests the safety of a drug called Anktiva in 40 adults with Long COVID—persistent symptoms after a COVID-19 infection. Participants receive the drug as a shot, and researchers monitor for side effects and changes in symptoms. The goal is to see if Anktiva is safe enough for further testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anktiva (also called nogapendekin alfa inbakicept or NAI)
What this could lead to: If it works, this could point toward a treatment for Long COVID symptoms like fatigue and brain fog.
What could go wrong: This is a small, early-phase trial focused on safety, not effectiveness. It may not show clear benefit, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LONG COVID LONG COVID SYNDROME LONG COVID-19

Contacts and locations

Locations

Chan Soon-Schiong Institute for Medicine (CSSIFM)
RECRUITING

El Segundo, California, 90245, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.